Cell-free urine- and plasma DNA mutational analysis predicts neoadjuvant chemotherapy response and outcome in patients with muscle invasive bladder cancer.
Emil ChristensenIver NordentoftKarin Birkenkamp-DemtröderSara K ElbækSia Viborg LindskrogAnn TaberTine G AndreasenTrine StrandgaardMichael KnudsenPhilippe LamyMads AgerbækJørgen Bjerggaard JensenLars DyrskjøtPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Analysis of tumor DNA in plasma and urine samples both separately and combined has potential to predict treatment response and outcome.